Decision: Favourable

Study Title:

A multicenter, open-label extension study to investigate the long-term safety of FAB122 in patients with Amyotrophic Lateral Sclerosis ADOREXT (ALS trial with Daily ORal Edaravone EXTension) study

  • NREC Code:

    23-NREC-CT-008

  • Decision:

    Favourable

  • Meeting Date:

    25/01/2023

  • Study Type:

    CT application

  • Principal Investigator:

    Prof Orla Hardiman

  • PI Institution:

    Beaumont Hospital

  • Sponsor:

    Ferrer Internacional, S.A

Scroll to Top